BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021] [Cited by in F6Publishing: 220] [Reference Citation Analysis]
Number Citing Articles
1 Wei AL, Li M, Li GQ, Wang X, Hu WM, Li ZL, Yuan J, Liu HY, Zhou LL, Li K, Li A, Fu MR. Oral microbiome and pancreatic cancer. World J Gastroenterol 2020; 26(48): 7679-7692 [PMID: 33505144 DOI: 10.3748/wjg.v26.i48.7679] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Kaur S, Smith LM, Patel A, Menning M, Watley DC, Malik SS, Krishn SR, Mallya K, Aithal A, Sasson AR, Johansson SL, Jain M, Singh S, Guha S, Are C, Raimondo M, Hollingsworth MA, Brand RE, Batra SK. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Am J Gastroenterol. 2017;112:172-183. [PMID: 27845339 DOI: 10.1038/ajg.2016.482] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 9.2] [Reference Citation Analysis]
3 Dasari BV, Roberts KJ, Hodson J, Stevens L, Smith AM, Hubscher SG, Isaac J, Muiesan P, Sutcliffe RP, Marudanayagam R, Mirza DF. A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio. HPB (Oxford) 2016;18:332-8. [PMID: 27037202 DOI: 10.1016/j.hpb.2015.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
4 Adekolujo OS, Agu C, Shamar I, Trauber D. Advanced Gastrointestinal Diffuse Large B-Cell Lymphoma Presenting with Obstructive Jaundice and Very High CA 19-9 Level Mimicking Pancreatic Adenocarcinoma. J Gastrointest Cancer 2016;47:100-3. [PMID: 25963397 DOI: 10.1007/s12029-015-9728-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Tanisaka Y, Mizuide M, Fujita A, Ogawa T, Suzuki M, Katsuda H, Saito Y, Miyaguchi K, Tashima T, Mashimo Y, Ryozawa S. Diagnostic Process Using Endoscopy for Biliary Strictures: A Narrative Review. J Clin Med 2021;10:1048. [PMID: 33802525 DOI: 10.3390/jcm10051048] [Reference Citation Analysis]
6 Accordino MK, Wright JD, Vasan S, Neugut AI, Tergas A, Hu JC, Hershman DL, Accordino MK, Wright JD, Vasan S, Neugut AI, Tergas A, Hu JC, Hershman DL. Serum Tumor Marker Use in Patients With Advanced Solid Tumors. J Oncol Pract 2016;12:65-6, e36-43. [PMID: 26374862 DOI: 10.1200/JOP.2015.005660] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
7 Soares JC, Iwaki LEO, Soares AC, Rodrigues VC, Melendez ME, Fregnani JHTG, Reis RM, Carvalho AL, Corrêa DS, Oliveira ON Jr. Immunosensor for Pancreatic Cancer Based on Electrospun Nanofibers Coated with Carbon Nanotubes or Gold Nanoparticles. ACS Omega 2017;2:6975-83. [PMID: 30023536 DOI: 10.1021/acsomega.7b01029] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 6.4] [Reference Citation Analysis]
8 Ge P, Luo Y, Chen H, Liu J, Guo H, Xu C, Qu J, Zhang G, Chen H. Application of Mass Spectrometry in Pancreatic Cancer Translational Research. Front Oncol 2021;11:667427. [PMID: 34707986 DOI: 10.3389/fonc.2021.667427] [Reference Citation Analysis]
9 Kulkarni NM, Soloff EV, Tolat PP, Sangster GP, Fleming JB, Brook OR, Wang ZJ, Hecht EM, Zins M, Bhosale PR, Arif-Tiwari H, Mannelli L, Kambadakone AR, Tamm EP. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdom Radiol (NY) 2020;45:716-28. [PMID: 31748823 DOI: 10.1007/s00261-019-02289-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
10 Lai HC, Lee MS, Liu YT, Lin KT, Hung KC, Chen JY, Wu ZF. Propofol-based intravenous anesthesia is associated with better survival than desflurane anesthesia in pancreatic cancer surgery. PLoS One 2020;15:e0233598. [PMID: 32437450 DOI: 10.1371/journal.pone.0233598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Maruyama H, Hanada K, Shimizu A, Minami T, Hirano N, Hino F, Abe T, Amano H, Fujiwara Y. Value of endoscopic ultrasonography in the observation of the remnant pancreas after pancreatectomy. PLoS One 2021;16:e0245447. [PMID: 33465138 DOI: 10.1371/journal.pone.0245447] [Reference Citation Analysis]
12 Amon R, Rosenfeld R, Perlmutter S, Grant OC, Yehuda S, Borenstein-Katz A, Alcalay R, Marshanski T, Yu H, Diskin R, Woods RJ, Chen X, Padler-Karavani V. Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in Cancer. Cancers (Basel) 2020;12:E2824. [PMID: 33007970 DOI: 10.3390/cancers12102824] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Yang GY, Malik NK, Chandrasekhar R, Ma WW, Flaherty L, Iyer R, Kuvshinoff B, Gibbs J, Wilding G, Warren G, May KS. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol 2013;4:361-9. [PMID: 24294507 DOI: 10.3978/j.issn.2078-6891.2013.045] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
14 Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H, Ochiai A. MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers. PLoS One. 2015;10:e0118220. [PMID: 25706130 DOI: 10.1371/journal.pone.0118220] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 10.1] [Reference Citation Analysis]
15 Zhou X, Huang Z, Xu L, Zhu M, Zhang L, Zhang H, Wang X, Li H, Zhu W, Shu Y, Liu P. A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget 2016;7:69616-24. [PMID: 27626307 DOI: 10.18632/oncotarget.11903] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
16 Long NP, Yoon SJ, Anh NH, Nghi TD, Lim DK, Hong YJ, Hong SS, Kwon SW. A systematic review on metabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer. Metabolomics 2018;14:109. [PMID: 30830397 DOI: 10.1007/s11306-018-1404-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
17 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015; 21(14): 4323-4333 [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
18 Song DH, Cho IK, Shin DW, Lee JC, Cho JY, Yoon YS, Hwang JH, Han HS, Kim J. The clinical significance of preoperative C-reactive protein/albumin ratio in patients with resected extrahepatic bile duct cancer. Surg Today 2021;51:978-85. [PMID: 33387024 DOI: 10.1007/s00595-020-02188-z] [Reference Citation Analysis]
19 Asar MC, Franco A, Soendergaard M. Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides. Biomolecules 2020;10:E714. [PMID: 32380649 DOI: 10.3390/biom10050714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhai S, Liu Y, Lu X, Qian H, Tang X, Cheng X, Wang Y, Shi Y, Deng X. INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT. Onco Targets Ther 2019;12:8287-99. [PMID: 31632078 DOI: 10.2147/OTT.S223221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
21 Qian H, Li H, Xie J, Lu X, Li F, Wang W, Tang X, Shi M, Jiang L, Li H, Chen H, Peng C, Xu Z, Deng X, Shen B. Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer. Front Cell Dev Biol 2021;9:682261. [PMID: 34249934 DOI: 10.3389/fcell.2021.682261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Fukutake N, Ueno M, Hiraoka N, Shimada K, Shiraishi K, Saruki N, Ito T, Yamakado M, Ono N, Imaizumi A, Kikuchi S, Yamamoto H, Katayama K. A Novel Multivariate Index for Pancreatic Cancer Detection Based On the Plasma Free Amino Acid Profile. PLoS One 2015;10:e0132223. [PMID: 26133769 DOI: 10.1371/journal.pone.0132223] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
23 Arivazhagan S, Kantamani D, Tanner NE, Kundranda MN, Stagg MP. Infection Masquerading as Recurrence of Pancreatic Ductal Adenocarcinoma: A Cautionary Tale. Cureus 2021;13:e17010. [PMID: 34540411 DOI: 10.7759/cureus.17010] [Reference Citation Analysis]
24 Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One. 2013;8:e67059. [PMID: 23840582 DOI: 10.1371/journal.pone.0067059] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
25 Akolkar D, Patil D, Crook T, Limaye S, Page R, Datta V, Patil R, Sims C, Ranade A, Fulmali P, Fulmali P, Srivastava N, Devhare P, Apurwa S, Patel S, Patil S, Adhav A, Pawar S, Ainwale A, Chougule R, Apastamb M, Srinivasan A, Datar R. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int J Cancer 2020;146:3485-94. [PMID: 31785151 DOI: 10.1002/ijc.32815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
26 Deng Y, Ma H, Hao J, Xie Q, Zhao R. MCM2 and NUSAP1 Are Potential Biomarkers for the Diagnosis and Prognosis of Pancreatic Cancer. Biomed Res Int 2020;2020:8604340. [PMID: 32420375 DOI: 10.1155/2020/8604340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Dumitra S, Jamal MH, Aboukhalil J, Doi SA, Chaudhury P, Hassanain M, Metrakos PP, Barkun JS. Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score. HPB (Oxford) 2013;15:1002-9. [PMID: 23521164 DOI: 10.1111/hpb.12085] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
28 Zou X, Wei J, Huang Z, Zhou X, Lu Z, Zhu W, Miao Y. Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. Cancer Med 2019;8:2810-22. [PMID: 31006985 DOI: 10.1002/cam4.2145] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
29 Earl J, Galindo-Pumariño C, Encinas J, Barreto E, Castillo ME, Pachón V, Ferreiro R, Rodríguez-Garrote M, González-Martínez S, Ramon Y Cajal T, Diaz LR, Chirivella-Gonzalez I, Rodriguez M, de Castro EM, García-Seisdedos D, Muñoz G, Rosa JMR, Marquez M, Malats N, Carrato A. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. EBioMedicine 2020;53:102675. [PMID: 32113160 DOI: 10.1016/j.ebiom.2020.102675] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
30 Kriz D, Ansari D, Andersson R. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma. Clin Transl Oncol. 2020;22:2170-2174. [PMID: 32447642 DOI: 10.1007/s12094-020-02372-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Almeida PP, Cardoso CP, de Freitas LM. PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression. BMC Cancer. 2020;20:82. [PMID: 32005189 DOI: 10.1186/s12885-020-6533-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
32 O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 2015;21:622-631. [PMID: 24938522 DOI: 10.1158/1078-0432.ccr-14-0365] [Cited by in Crossref: 101] [Cited by in F6Publishing: 65] [Article Influence: 12.6] [Reference Citation Analysis]
33 Le Large TYS, Meijer LL, Paleckyte R, Boyd LNC, Kok B, Wurdinger T, Schelfhorst T, Piersma SR, Pham TV, van Grieken NCT, Zonderhuis BM, Daams F, van Laarhoven HWM, Bijlsma MF, Jimenez CR, Giovannetti E, Kazemier G. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. Oncologist. 2020;25:e634-e643. [PMID: 31943574 DOI: 10.1634/theoncologist.2019-0680] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
34 Khandelwal A, Inoue D, Takahashi N. Autoimmune pancreatitis: an update. Abdom Radiol (NY) 2020;45:1359-70. [PMID: 31650376 DOI: 10.1007/s00261-019-02275-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
35 Zhang Z, Wuhrer M, Holst S. Serum sialylation changes in cancer. Glycoconj J 2018;35:139-60. [PMID: 29680984 DOI: 10.1007/s10719-018-9820-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 14.0] [Reference Citation Analysis]
36 Loft M, Lee B, Tie J, Gibbs P. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. J Pers Med 2019;9:E37. [PMID: 31323810 DOI: 10.3390/jpm9030037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
37 Lin S, Fang Y, Mo Z, Lin Y, Ji C, Jian Z. Prognostic value of lymphocyte to monocyte ratio in pancreatic cancer: a systematic review and meta-analysis including 3338 patients. World J Surg Oncol 2020;18:186. [PMID: 32711514 DOI: 10.1186/s12957-020-01962-0] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bergheim J, Semaan A, Gevensleben H, Groening S, Knoblich A, Dietrich J, Weber J, Kalff JC, Bootz F, Kristiansen G, Dietrich D. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: A prospective observational cohort study. Br J Cancer. 2018;118:1217-1228. [PMID: 29610456 DOI: 10.1038/s41416-018-0035-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
39 Mattiucci GC, Morganti AG, Cellini F, Buwenge M, Casadei R, Farioli A, Alfieri S, Arcelli A, Bertini F, Calvo FA, Cammelli S, Fuccio L, Giaccherini L, Guido A, Herman JM, Macchia G, Maidment BW 3rd, Miller RC, Minni F, Regine WF, Reni M, Partelli S, Falconi M, Valentini V. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Transl Oncol 2019;12:1-7. [PMID: 30237099 DOI: 10.1016/j.tranon.2018.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
40 Roa-Peña L, Leiton CV, Babu S, Pan CH, Vanner EA, Akalin A, Bandovic J, Moffitt RA, Shroyer KR, Escobar-Hoyos LF. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Sci Rep 2019;9:11239. [PMID: 31375762 DOI: 10.1038/s41598-019-47519-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
41 Ma C, Jiang F, Ma Y, Wang J, Li H, Zhang J. Isolation and Detection Technologies of Extracellular Vesicles and Application on Cancer Diagnostic. Dose Response 2019;17:1559325819891004. [PMID: 31839757 DOI: 10.1177/1559325819891004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
42 Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy C, Sergé A, Lavaut MN, Dusetti N, Loncle C, Roques J, Pietrasz D, Bousquet C, Garcia S, Granjeaud S, Ouaissi M, Bachet JB, Brun C, Iovanna JL, Zimmermann P, Vasseur S, Tomasini R. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest 2016;126:4140-56. [PMID: 27701147 DOI: 10.1172/JCI87734] [Cited by in Crossref: 107] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
43 Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3641-8. [PMID: 32234757 DOI: 10.1158/1078-0432.CCR-19-4044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
44 Palumbo D, Mori M, Prato F, Crippa S, Belfiori G, Reni M, Mushtaq J, Aleotti F, Guazzarotti G, Cao R, Steidler S, Tamburrino D, Spezi E, Del Vecchio A, Cascinu S, Falconi M, Fiorino C, De Cobelli F. Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Cancers (Basel) 2021;13:4938. [PMID: 34638421 DOI: 10.3390/cancers13194938] [Reference Citation Analysis]
45 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
46 Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, Keeley BP, Stark A, Herrera A, Wolfgang C. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19:6544-6555. [PMID: 24088737 DOI: 10.1158/1078-0432.ccr-12-3224] [Cited by in Crossref: 84] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
47 Sperti C, Moletta L, Merigliano S. Multimodality treatment of recurrent pancreatic cancer: Mith or reality? World J Gastrointest Oncol 2015; 7(12): 375-382 [PMID: 26689800 DOI: 10.4251/wjgo.v7.i12.375] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
48 Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, Ishikawa H, Kakizawa N, Saito M, Futsuhara K, Noda H, Konishi F, Rikiyama T. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS One 2019;14:e0227366. [PMID: 31891652 DOI: 10.1371/journal.pone.0227366] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
49 Xu Y, Liu P, Zheng DH, Wu N, Zhu L, Xing C, Zhu J. Expression profile and prognostic value of NNMT in patients with pancreatic cancer. Oncotarget 2016;7:19975-81. [PMID: 26942567 DOI: 10.18632/oncotarget.7891] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
50 Huo Z, Zhai S, Weng Y, Qian H, Tang X, Shi Y, Deng X, Wang Y, Shen B. PRPF40A as a potential diagnostic and prognostic marker is upregulated in pancreatic cancer tissues and cell lines: an integrated bioinformatics data analysis. Onco Targets Ther 2019;12:5037-51. [PMID: 31303762 DOI: 10.2147/OTT.S206039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
51 Almadi MA, Alharbi O, Azzam N, Altayeb M, Javed M, Alsaif F, Hassanain M, Alsharabi A, Al-Saleh K, Aljebreen AM. Clinical predictors of resectability of pancreatic adenocarcinoma. Saudi J Gastroenterol 2013;19:278-85. [PMID: 24195982 DOI: 10.4103/1319-3767.121036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
52 Nista EC, Schepis T, Candelli M, Giuli L, Pignataro G, Franceschi F, Gasbarrini A, Ojetti V. Humoral Predictors of Malignancy in IPMN: A Review of the Literature. Int J Mol Sci 2021;22:12839. [PMID: 34884643 DOI: 10.3390/ijms222312839] [Reference Citation Analysis]
53 Zhou YY, Chen LP, Zhang Y, Hu SK, Dong ZJ, Wu M, Chen QX, Zhuang ZZ, Du XJ. Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer. Mol Med 2019;25:47. [PMID: 31706267 DOI: 10.1186/s10020-019-0113-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
54 Burns EA, Kasparian S, Khan U, Abdelrahim M. Pancreatic adenocarcinoma with early esophageal metastasis: A case report and review of literature. World J Clin Oncol 2020; 11(2): 83-90 [PMID: 32133277 DOI: 10.5306/wjco.v11.i2.83] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Zeng C, Zhang Z, Wang J, Chiu BC, Hou L, Zhang W. Application of the High-throughput TAB-Array for the Discovery of Novel 5-Hydroxymethylcytosine Biomarkers in Pancreatic Ductal Adenocarcinoma. Epigenomes 2019;3:16. [PMID: 31413874 DOI: 10.3390/epigenomes3030016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
56 Blanas A, Sahasrabudhe NM, Rodríguez E, van Kooyk Y, van Vliet SJ. Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy. Front Oncol 2018;8:39. [PMID: 29527514 DOI: 10.3389/fonc.2018.00039] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
57 Hanada K, Amano H, Abe T. Early diagnosis of pancreatic cancer: Current trends and concerns. Ann Gastroenterol Surg 2017;1:44-51. [PMID: 29863166 DOI: 10.1002/ags3.12004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
58 Hong S, Song KB, Hwang DW, Lee JH, Lee W, Jun E, Kwon J, Park Y, Park SY, Kim N, Shin D, Kim H, Sung M, Ryu Y, Kim SC. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. World J Gastrointest Surg 2021; 13(11): 1423-1435 [DOI: 10.4240/wjgs.v13.i11.1423] [Reference Citation Analysis]
59 Chandler K, Goldman R. Glycoprotein disease markers and single protein-omics. Mol Cell Proteomics. 2013;12:836-845. [PMID: 23399550 DOI: 10.1074/mcp.R112.026930] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 4.9] [Reference Citation Analysis]
60 Ji F, Fu SJ, Guo ZY, Pang H, Ju WQ, Wang DP, Hua YP, He XS. Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2016;95:e4065. [PMID: 27399091 DOI: 10.1097/MD.0000000000004065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
61 Choi YJ, Yoon W, Lee A, Han Y, Byun Y, Kang JS, Kim H, Kwon W, Suh YA, Kim Y, Lee S, Namkung J, Han S, Choi Y, Heo JS, Park JO, Park JK, Kim SC, Kang CM, Lee WJ, Park T, Jang JY. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Ann Surg Treat Res 2021;100:144-53. [PMID: 33748028 DOI: 10.4174/astr.2021.100.3.144] [Reference Citation Analysis]
62 Russ E, Bhuvaneshwar K, Wang G, Jin B, Gage MM, Madhavan S, Gusev Y, Upadhyay G. High mRNA expression of LY6 gene family is associated with overall survival outcome in pancreatic ductal adenocarcinoma. Oncotarget 2021;12:145-59. [PMID: 33613843 DOI: 10.18632/oncotarget.27880] [Reference Citation Analysis]
63 Winter K, Talar-Wojnarowska R, Dąbrowski A, Degowska M, Durlik M, Gąsiorowska A, Głuszek S, Jurkowska G, Kaczka A, Lampe P, Marek T, Nasierowska-Guttmejer A, Nowakowska-Duława E, Rydzewska G, Strzelczyk J, Śledziński Z, Małecka-Panas E. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Prz Gastroenterol 2019;14:1-18. [PMID: 30944673 DOI: 10.5114/pg.2019.83422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
64 Setti G, Pezzi ME, Viani MV, Pertinhez TA, Cassi D, Magnoni C, Bellini P, Musolino A, Vescovi P, Meleti M. Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review. Int J Mol Sci. 2020;21. [PMID: 32019170 DOI: 10.3390/ijms21030907] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
65 Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today 2020;50:1117-25. [PMID: 32474642 DOI: 10.1007/s00595-020-02028-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
66 Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562 [PMID: 27559435 DOI: 10.4251/wjgo.v8.i7.555] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
67 Vila-Navarro E, Duran-Sanchon S, Vila-Casadesús M, Moreira L, Ginès À, Cuatrecasas M, Lozano JJ, Bujanda L, Castells A, Gironella M. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia. Clin Transl Gastroenterol 2019;10:e00029. [PMID: 31009404 DOI: 10.14309/ctg.0000000000000029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
68 Zhang Q, Qu H, Sun G, Li Z, Ma S, Shi Z, Zhao E, Zhang H, He Q. Early postoperative tumor marker responses provide a robust prognostic indicator for N3 stage gastric cancer. Medicine (Baltimore). 2017;96:e7560. [PMID: 28796039 DOI: 10.1097/md.0000000000007560] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
69 Shi C, van der Wal HH, Silljé HHW, Dokter MM, van den Berg F, Huizinga L, Vriesema M, Post J, Anker SD, Cleland JG, Ng LL, Samani NJ, Dickstein K, Zannad F, Lang CC, van Haelst PL, Gietema JA, Metra M, Ameri P, Canepa M, van Veldhuisen DJ, Voors AA, de Boer RA. Tumour biomarkers: association with heart failure outcomes. J Intern Med 2020;288:207-18. [PMID: 32372544 DOI: 10.1111/joim.13053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
70 Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, Sheinin Y, Rachagani S, Natarajan G, Brand RE, Macha MA, Grandgenett PM, Kaur S, Batra SK. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. EBioMedicine. 2019;42:375-385. [PMID: 30956167 DOI: 10.1016/j.ebiom.2019.03.056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
71 Durczynski A, Skulimowski A, Hogendorf P, Szymanski D, Kumor A, Marski K, Juliebø SØ, Poznanska G, Strzelczyk J. The concentration of D-dimers in portal blood positively correlates with overall survival in patients with non-resectable pancreatic cancer. World J Surg Oncol 2017;15:223. [PMID: 29246148 DOI: 10.1186/s12957-017-1291-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
72 Hufnagl C, Leisch M, Weiss L, Melchardt T, Moik M, Asslaber D, Roland G, Steininger P, Meissnitzer T, Neureiter D, Greil R, Egle A. Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer. Oncol Lett 2020;19:1551-8. [PMID: 31966080 DOI: 10.3892/ol.2019.11192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
73 Ritchie SA, Chitou B, Zheng Q, Jayasinghe D, Jin W, Mochizuki A, Goodenowe DB. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9. World J Gastroenterol 2015; 21(21): 6604-6612 [PMID: 26074698 DOI: 10.3748/wjg.v21.i21.6604] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
74 Goto T, Fujiya M, Konishi H, Sasajima J, Fujibayashi S, Hayashi A, Utsumi T, Sato H, Iwama T, Ijiri M, Sakatani A, Tanaka K, Nomura Y, Ueno N, Kashima S, Moriichi K, Mizukami Y, Kohgo Y, Okumura T. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker. BMC Cancer. 2018;18:116. [PMID: 29385987 DOI: 10.1186/s12885-018-4006-5] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 19.5] [Reference Citation Analysis]
75 Usón Junior PLS, Callegaro-Filho D, Bugano DDG, Moura F, Maluf FC. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. J Gastrointest Cancer 2018;49:481-6. [PMID: 28924968 DOI: 10.1007/s12029-017-0007-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
76 Penafuerte C, Feldhammer M, Mills JR, Vinette V, Pike KA, Hall A, Migon E, Karsenty G, Pelletier J, Zogopoulos G, Tremblay ML. Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling. Oncoimmunology 2017;6:e1321185. [PMID: 28680757 DOI: 10.1080/2162402X.2017.1321185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
77 Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C, Perdrix A, Paresy M, Antonietti M, Iwanicki-Caron I. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017;117:1017-1025. [PMID: 28772284 DOI: 10.1038/bjc.2017.250] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 10.4] [Reference Citation Analysis]
78 Kishikawa T, Otsuka M, Yoshikawa T, Ohno M, Yamamoto K, Yamamoto N, Kotani A, Koike K. Quantitation of circulating satellite RNAs in pancreatic cancer patients. JCI Insight 2016;1:e86646. [PMID: 27699267 DOI: 10.1172/jci.insight.86646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
79 Yu Z, Chen Z, Wu J, Li Z, Wu Y. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis. PLoS One. 2017;12:e0188139. [PMID: 29141049 DOI: 10.1371/journal.pone.0188139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
80 Wu J, Wu M, Wu Q. Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics. J Clin Lab Anal 2020;34:e23333. [PMID: 32281150 DOI: 10.1002/jcla.23333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
81 Garnier J, Robin F, Ewald J, Marchese U, Bergeat D, Boudjema K, Delpero JR, Sulpice L, Turrini O. Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery? Ann Surg Oncol 2021;28:4625-34. [PMID: 33462718 DOI: 10.1245/s10434-020-09520-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Tanisaka Y, Mizuide M, Fujita A, Ogawa T, Katsuda H, Saito Y, Miyaguchi K, Jinushi R, Terada R, Nakano Y, Tashima T, Mashimo Y, Ryozawa S. Current Status of Endoscopic Biliary Drainage in Patients with Distal Malignant Biliary Obstruction. J Clin Med 2021;10:4619. [PMID: 34640637 DOI: 10.3390/jcm10194619] [Reference Citation Analysis]
83 Tu J, Huang Z, Wang Y, Wang M, Yin Z, Mei X, Li M, Li L. Transcriptome analysis of the procession from chronic pancreatitis to pancreatic cancer and metastatic pancreatic cancer. Sci Rep 2021;11:3409. [PMID: 33564087 DOI: 10.1038/s41598-021-83015-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B, Søreide JA, Javle M, Nordgård O, Smaaland R. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol 2016;10:635-43. [PMID: 26725968 DOI: 10.1016/j.molonc.2015.11.012] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 12.3] [Reference Citation Analysis]
85 Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019;13:410. [PMID: 31044028 DOI: 10.4081/oncol.2019.410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
86 Moschovis D, Gazouli M, Tzouvala M, Vezakis A, Karamanolis G. Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors. Ann Gastroenterol 2017;30:622-8. [PMID: 29118556 DOI: 10.20524/aog.2017.0185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
87 Yuan W, Tang W, Xie Y, Wang S, Chen Y, Qi J, Qiao Y, Ma J. New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer. Oncotarget 2016;7:80033-45. [PMID: 27713117 DOI: 10.18632/oncotarget.12406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
88 Yegya-Raman N, Shah MM, Grandhi MS, Poplin E, August DA, Kennedy TJ, Malhotra U, Spencer KR, Carpizo DR, Jabbour SK. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Ann Pancreat Cancer 2018;1:20. [PMID: 30687847 DOI: 10.21037/apc.2018.07.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol 2018; 24(19): 2047-2060 [PMID: 29785074 DOI: 10.3748/wjg.v24.i19.2047] [Cited by in CrossRef: 108] [Cited by in F6Publishing: 89] [Article Influence: 27.0] [Reference Citation Analysis]
90 Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A, Scholz WW, Zeglis BM, Lewis JS. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2019;25:868-80. [PMID: 30352909 DOI: 10.1158/1078-0432.CCR-18-1650] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
91 Lee DW, Im SA, Kim YJ, Yang Y, Rhee J, Na II, Lee KH, Kim TY, Han SW, Choi IS, Oh DY, Kim JH, Kim TY, Bang YJ. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. Cancer Res Treat 2017;49:807-15. [PMID: 28111425 DOI: 10.4143/crt.2016.326] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
92 Kotzev AI, Draganov PV. Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing? Gastrointest Tumors. 2018;5:1-13. [PMID: 30574476 DOI: 10.1159/000488240] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
93 Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. PLoS Med 2020;17:e1003489. [PMID: 33301466 DOI: 10.1371/journal.pmed.1003489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
94 Naseer M, Hadi S, Syed A, Safdari A, Tahan V. Exosomes: A new frontier under the spotlight for diagnosis and treatment of gastrointestinal diseases. World J Meta-Anal 2021; 9(1): 12-28 [DOI: 10.13105/wjma.v9.i1.12] [Reference Citation Analysis]
95 Giannis D, Moris D, Barbas AS. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians. Cancers (Basel) 2021;13:1071. [PMID: 33802340 DOI: 10.3390/cancers13051071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Chen X, Liu F, Xue Q, Weng X, Xu F. Metastatic pancreatic cancer: Mechanisms and detection (Review). Oncol Rep 2021;46:231. [PMID: 34498718 DOI: 10.3892/or.2021.8182] [Reference Citation Analysis]
97 Zhang J, Wang Y, Zhao T, Li Y, Tian L, Zhao J, Zhang J. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer. World J Surg Oncol 2020;18:31. [PMID: 32028958 DOI: 10.1186/s12957-020-1809-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
98 Fiala O, Hosek P, Sorejs O, Liska V, Buchler T, Poprach A, Kucera R, Topolcan O, Sedivcova M, Finek J. The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line. J Cancer 2018;9:4255-62. [PMID: 30519327 DOI: 10.7150/jca.26217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
99 Suh HN, Jun S, Oh AY, Srivastava M, Lee S, Taniguchi CM, Zhang S, Lee WS, Chen J, Park BJ, Park JI. Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia. Sci Rep 2016;6:38273. [PMID: 27922049 DOI: 10.1038/srep38273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
100 Shen Y, Zhu X, Cao F, Xie H, Ju X, Cao Y, Qing S, Jia Z, Gu L, Fang F, Zhang H. Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases. Front Oncol 2021;11:729490. [PMID: 34796108 DOI: 10.3389/fonc.2021.729490] [Reference Citation Analysis]
101 Yee NS, Zhang S, He HZ, Zheng SY. Extracellular Vesicles as Potential Biomarkers for Early Detection and Diagnosis of Pancreatic Cancer. Biomedicines 2020;8:E581. [PMID: 33297544 DOI: 10.3390/biomedicines8120581] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
102 Liang K, Liu F, Fan J, Sun D, Liu C, Lyon CJ, Bernard DW, Li Y, Yokoi K, Katz MH, Koay EJ, Zhao Z, Hu Y. Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. Nat Biomed Eng 2017;1:0021. [PMID: 28791195 DOI: 10.1038/s41551-016-0021] [Cited by in Crossref: 158] [Cited by in F6Publishing: 155] [Article Influence: 31.6] [Reference Citation Analysis]
103 Houghton JL, Abdel-Atti D, Scholz WW, Lewis JS. Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with 89Zr-5B1. Mol Pharm 2017;14:908-15. [PMID: 28191976 DOI: 10.1021/acs.molpharmaceut.6b01130] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
104 Perets R, Greenberg O, Shentzer T, Semenisty V, Epelbaum R, Bick T, Sarji S, Ben-Izhak O, Sabo E, Hershkovitz D. Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. Oncologist 2018;23:566-72. [PMID: 29371474 DOI: 10.1634/theoncologist.2017-0467] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
105 van Veldhuisen E, van den Oord C, Brada LJ, Walma MS, Vogel JA, Wilmink JW, Del Chiaro M, van Lienden KP, Meijerink MR, van Tienhoven G, Hackert T, Wolfgang CL, van Santvoort H, Groot Koerkamp B, Busch OR, Molenaar IQ, van Eijck CH, Besselink MG; Dutch Pancreatic Cancer Group and International Collaborative Group on Locally Advanced Pancreatic Cancer. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers (Basel) 2019;11:E976. [PMID: 31336859 DOI: 10.3390/cancers11070976] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
106 Ehlken H, Schramm C. How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed? Viszeralmedizin 2015;31:173-7. [PMID: 26468311 DOI: 10.1159/000431350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
107 Smith LA, Jamieson NB, McKay CJ. Investigation and management of pancreatic tumours. Frontline Gastroenterol 2014;5:144-52. [PMID: 28839761 DOI: 10.1136/flgastro-2013-100364] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Xu HN, Nioka S, Li LZ. Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse model. Biomark Res 2013;1:6. [PMID: 24252270 DOI: 10.1186/2050-7771-1-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
109 Wáng YX, Gong JS, Loffroy R. On pancreatic cancer screening by magnetic resonance imaging with the recent evidence by Del Chiaro and colleagues. Chin J Cancer Res 2015;27:417-22. [PMID: 26361411 DOI: 10.3978/j.issn.1000-9604.2015.06.09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Bae JS, Kim JH, Joo I, Chang W, Han JK. MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer. Eur Radiol 2019;29:3714-24. [PMID: 30899975 DOI: 10.1007/s00330-019-06140-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
111 Yi N, Zhao X, Ji J, Xu M, Jiao Y, Qian T, Zhu S, Jiang F, Chen J, Xiao M. Serum galectin-3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer. J Cell Mol Med. 2020;24:11583-11591. [PMID: 32886424 DOI: 10.1111/jcmm.15775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
112 Alsaleh M, Barbera TA, Reeves HL, Cramp ME, Ryder S, Gabra H, Nash K, Shen YL, Holmes E, Williams R, Taylor-Robinson SD. Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population. Hepat Med 2019;11:47-67. [PMID: 31118840 DOI: 10.2147/HMER.S193996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
113 Al-Shamsi HO, Alzahrani M, Wolff RA. The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol 2016;7:E45-51. [PMID: 27284488 DOI: 10.21037/jgo.2016.01.05] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
114 Akimoto S, Banshodani M, Nishihara M, Nambu J, Kawaguchi Y, Shimamoto F, Dohi K, Sugino K, Ohdan H. Acute Cholecystitis with Significantly Elevated Levels of Serum Carbohydrate Antigen 19-9. Case Rep Gastroenterol. 2016;10:410-416. [PMID: 27721726 DOI: 10.1159/000448068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
115 King DA, Pineda G, Jhun I, Fisher G. Marked Decrease in CA 19-9 Level Belies Rapidly Progressive Lymphangitic Carcinomatosis in a Case of Metastatic Pancreatic Cancer. J Pancreat Cancer 2020;6:102-6. [PMID: 33269335 DOI: 10.1089/pancan.2020.0015] [Reference Citation Analysis]
116 Nurmi AM, Mustonen HK, Stenman UH, Seppänen HE, Haglund CH. Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma. Sci Rep 2021;11:781. [PMID: 33437015 DOI: 10.1038/s41598-020-80778-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Li H, Wang X, Fang Y, Huo Z, Lu X, Zhan X, Deng X, Peng C, Shen B. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Oncotarget 2017;8:52571-83. [PMID: 28881752 DOI: 10.18632/oncotarget.16732] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
118 Navaneethan U, Lourdusamy V, Gk Venkatesh P, Willard B, Sanaka MR, Parsi MA. Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study. Gastroenterol Rep (Oxf) 2015;3:136-43. [PMID: 25304323 DOI: 10.1093/gastro/gou066] [Cited by in Crossref: 27] [Cited by in F6Publishing: 73] [Article Influence: 3.4] [Reference Citation Analysis]
119 Morris-Stiff G, Taylor MA. Ca19-9 and pancreatic cancer: Is it really that good? J Gastrointest Oncol. 2012;3:88-89. [PMID: 22811875 DOI: 10.3978/j.issn.2078-6891.2012.016] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
120 Sancho-Albero M, Sebastián V, Sesé J, Pazo-Cid R, Mendoza G, Arruebo M, Martín-Duque P, Santamaría J. Isolation of exosomes from whole blood by a new microfluidic device: proof of concept application in the diagnosis and monitoring of pancreatic cancer. J Nanobiotechnology 2020;18:150. [PMID: 33092584 DOI: 10.1186/s12951-020-00701-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
121 Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci. 2017;18. [PMID: 28335509 DOI: 10.3390/ijms18030667] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
122 Zhu L, Guo J, Jin Z, Xue H, Dai M, Zhang W, Sun Z, Xu J, Marticorena Garcia SR, Asbach P, Hamm B, Sack I. Distinguishing pancreatic cancer and autoimmune pancreatitis with in vivo tomoelastography. Eur Radiol 2021;31:3366-74. [PMID: 33125553 DOI: 10.1007/s00330-020-07420-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
123 Lu LH, Zhang YF, Wei W, Shi M, Guo RP. Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. J Gastrointest Surg. 2017;21:2025-2032. [PMID: 28840443 DOI: 10.1007/s11605-017-3528-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
124 Hsu CC, Goyal A, Iuga A, Krishnamoorthy S, Lee V, Verna EC, Wang S, Chen FN, Rodriguez R, Emond J, Berk P, Lefkowitch J, Dove L, Brown RS Jr, Siegel AB. Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients. Clin Transl Gastroenterol 2015;6:e74. [PMID: 25651978 DOI: 10.1038/ctg.2014.22] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
125 Salah M, Shaheen I, El-Shanawany P, Saad NE, Saad R, El Guibaly M, Momen N. Detection of miR-1246, miR-23a and miR-451 in sera of colorectal carcinoma patients: a case-control study in Cairo University hospital. Afr Health Sci 2020;20:1283-91. [PMID: 33402976 DOI: 10.4314/ahs.v20i3.33] [Reference Citation Analysis]
126 Yang Y, Yan S, Tian H, Bao Y. Macrophage inhibitory cytokine-1 vs carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies. Medicine (Baltimore). 2018;97:e9994. [PMID: 29489701 DOI: 10.1097/md.0000000000009994] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
127 Al-Fatlawi A, Malekian N, García S, Henschel A, Kim I, Dahl A, Jahnke B, Bailey P, Bolz SN, Poetsch AR, Mahler S, Grützmann R, Pilarsky C, Schroeder M. Deep Learning Improves Pancreatic Cancer Diagnosis Using RNA-Based Variants. Cancers (Basel) 2021;13:2654. [PMID: 34071263 DOI: 10.3390/cancers13112654] [Reference Citation Analysis]
128 Herreros-Villanueva M, Bujanda L. Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. Ann Transl Med. 2016;4:134. [PMID: 27162784 DOI: 10.21037/atm.2016.03.44] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
129 Fiala O, Finek J, Buchler T, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Liska V, Topolcan O. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study. Target Oncol 2015;10:549-55. [PMID: 25875421 DOI: 10.1007/s11523-015-0365-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
130 Gu X, Liu R. Application of 18F-FDG PET/CT combined with carbohydrate antigen 19-9 for differentiating pancreatic carcinoma from chronic mass-forming pancreatitis in Chinese elderly. Clin Interv Aging 2016;11:1365-70. [PMID: 27729779 DOI: 10.2147/CIA.S115254] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
131 Dimastromatteo J, Houghton JL, Lewis JS, Kelly KA. Challenges of Pancreatic Cancer. Cancer J. 2015;21:188-193. [PMID: 26049698 DOI: 10.1097/ppo.0000000000000109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
132 Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10:473-510. [PMID: 25621663 DOI: 10.1146/annurev-pathol-012414-040438] [Cited by in Crossref: 360] [Cited by in F6Publishing: 340] [Article Influence: 51.4] [Reference Citation Analysis]
133 Recio-Boiles A, Nallagangula A, Veeravelli S, Vondrak J, Saboda K, Roe D, Elquza E, McBride A, Babiker HM. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma. Ann Pancreat Cancer. 2019;2. [PMID: 31360919 DOI: 10.21037/apc.2019.06.01] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
134 Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel) 2018;10:E24. [PMID: 29361690 DOI: 10.3390/cancers10010024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
135 Zeeshan MS, Ramzan Z. Current controversies and advances in the management of pancreatic adenocarcinoma. World J Gastrointest Oncol 2021; 13(6): 472-494 [PMID: 34163568 DOI: 10.4251/wjgo.v13.i6.472] [Reference Citation Analysis]
136 Park SJ, Kim JH, Joo I, Lee KB, Han JK. Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX. Eur Radiol 2021;31:3616-26. [PMID: 33201279 DOI: 10.1007/s00330-020-07489-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Khatri I, Bhasin MK. A Transcriptomics-Based Meta-Analysis Combined With Machine Learning Identifies a Secretory Biomarker Panel for Diagnosis of Pancreatic Adenocarcinoma. Front Genet 2020;11:572284. [PMID: 33133160 DOI: 10.3389/fgene.2020.572284] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
138 Jin XL, Xu B, Wu YL. Detection of pancreatic cancer with normal carbohydrate antigen 19-9 using protein chip technology. World J Gastroenterol 2014; 20(40): 14958-14964 [PMID: 25356057 DOI: 10.3748/wjg.v20.i40.14958] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
139 Majumder S, Chari ST, Ahlquist DA. Molecular detection of pancreatic neoplasia: Current status and future promise. World J Gastroenterol 2015; 21(40): 11387-11395 [PMID: 26526068 DOI: 10.3748/wjg.v21.i40.11387] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
140 Song XH, Liu K, Yang SJ, Zhang WH, Chen XL, Zhao LY, Chen XZ, Yang K, Zhou ZG, Hu JK. Prognostic Value of Changes in Preoperative and Postoperative Serum CA19-9 Levels in Gastric Cancer. Front Oncol 2020;10:1432. [PMID: 33014781 DOI: 10.3389/fonc.2020.01432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Krishnan S, Whitwell HJ, Cuenco J, Gentry-Maharaj A, Menon U, Pereira SP, Gaspari M, Timms JF. Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. Int J Mol Sci. 2017;18. [PMID: 29232830 DOI: 10.3390/ijms18122670] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
142 Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer 2013;119:522-8. [PMID: 22898932 DOI: 10.1002/cncr.27762] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
143 Xu H, Zhang L, Kang H, Liu J, Zhang J, Zhao J, Liu S. Metabolomics Identifies Biomarker Signatures to Differentiate Pancreatic Cancer from Type 2 Diabetes Mellitus in Early Diagnosis. Int J Endocrinol 2021;2021:9990768. [PMID: 34868309 DOI: 10.1155/2021/9990768] [Reference Citation Analysis]
144 Gallmeier E, Gress TM. [Pancreatic ductal adenocarcinoma]. Internist (Berl). 2018;59:805-822. [PMID: 29980819 DOI: 10.1007/s00108-018-0460-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
145 Kurahara H, Mataki Y, Idichi T, Iino S, Kawasaki Y, Arigami T, Mori S, Sasaki K, Shinchi H, Ohtsuka T. Effectiveness of Adjuvant Therapy in Patients with Pancreatic Cancer Who Underwent Neoadjuvant Therapy. Ann Surg Oncol 2021. [PMID: 33606140 DOI: 10.1245/s10434-021-09712-6] [Reference Citation Analysis]
146 Michael Traeger M, Rehkaemper J, Ullerich H, Steinestel K, Wardelmann E, Senninger N, Abdallah Dhayat S. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol 2018;144:2419-31. [DOI: 10.1007/s00432-018-2755-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
147 Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 2013;34:3279-3292. [PMID: 23949878 DOI: 10.1007/s13277-013-1033-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 7.7] [Reference Citation Analysis]
148 Pandiaraja J, Viswanathan S, Antomy TB, Thirumuruganand S, Kumaresan DS. The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas. J Clin Diagn Res 2016;10:PC06-9. [PMID: 27134925 DOI: 10.7860/JCDR/2016/17106.7398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
149 Sivapalan L, Kocher HM, Ross-Adams H, Chelala C. Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application. Pancreatology. 2021;21:363-378. [PMID: 33451936 DOI: 10.1016/j.pan.2020.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Zhang J, Ten Dijke P, Wuhrer M, Zhang T. Role of glycosylation in TGF-β signaling and epithelial-to-mesenchymal transition in cancer. Protein Cell 2021;12:89-106. [PMID: 32583064 DOI: 10.1007/s13238-020-00741-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
151 Karandish F, Mallik S. Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomark Cancer 2016;8:27-35. [PMID: 27147897 DOI: 10.4137/BiC.s34414] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
152 Wu J, Tian ZB, Zhao QX, Kong XJ, Liu SL, Li XY. Pancreatic carcinoma with acute pancreatitis as the first manifestation: A case report and literature review. Shijie Huaren Xiaohua Zazhi 2016; 24(31): 4319-4322 [DOI: 10.11569/wcjd.v24.i31.4319] [Reference Citation Analysis]
153 O'Neill RS, Stoita A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol 2021; 27(26): 4045-4087 [PMID: 34326612 DOI: 10.3748/wjg.v27.i26.4045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
154 Duan X, Zhao L, Dong H, Zhao W, Liu S, Sui G. Microfluidic Immunoassay System for Rapid Detection and Semi-Quantitative Determination of a Potential Serum Biomarker Mesothelin. ACS Sens 2019;4:2952-7. [DOI: 10.1021/acssensors.9b01430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
155 Choi YH, Lee SH, You MS, Shin BS, Paik WH, Ryu JK, Kim YT, Kwon W, Jang JY, Kim SW. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. Gut Liver 2021;15:315-23. [PMID: 32235008 DOI: 10.5009/gnl19182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Borenstein-Katz A, Warszawski S, Amon R, Eilon M, Cohen-Dvashi H, Leviatan Ben-Arye S, Tasnima N, Yu H, Chen X, Padler-Karavani V, Fleishman SJ, Diskin R. Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies. J Mol Biol 2021;433:167099. [PMID: 34119488 DOI: 10.1016/j.jmb.2021.167099] [Reference Citation Analysis]
157 Dhayat SA, Traeger MM, Rehkaemper J, Stroese AJ, Steinestel K, Wardelmann E, Kabar I, Senninger N. Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2018;10:E328. [PMID: 30217058 DOI: 10.3390/cancers10090328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
158 Uddin MH, Al-Hallak MN, Philip PA, Mohammad RM, Viola N, Wagner KU, Azmi AS. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Cancers (Basel) 2021;13:2777. [PMID: 34204940 DOI: 10.3390/cancers13112777] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
159 Kinh Do R, Reyngold M, Paudyal R, Oh JH, Konar AS, LoCastro E, Goodman KA, Shukla-Dave A. Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminary Findings. Tomography 2020;6:261-71. [PMID: 32548304 DOI: 10.18383/j.tom.2020.00015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
160 Gao Z, Jiang W, Zhang S, Li P. The State of the Art on Blood MicroRNAs in Pancreatic Ductal Adenocarcinoma. Anal Cell Pathol (Amst) 2019;2019:9419072. [PMID: 31583198 DOI: 10.1155/2019/9419072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Szwedziak K, Szymański D, Strzelczyk J. CA 125 concentration in portal blood as a predictor of resectability in pancreatic tumor. Contemp Oncol (Pozn) 2013;17:394-9. [PMID: 24592129 DOI: 10.5114/wo.2013.35057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Park HS, Lee HS, Park JS, Park JS, Lee DK, Lee SJ, Yoon DS, Lee MG, Jeung HC. Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Res Treat 2016;48:1253-63. [PMID: 26875200 DOI: 10.4143/crt.2015.400] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
163 Guz M, Jeleniewicz W, Cybulski M, Kozicka J, Kurzepa J, Mądro A. Serum miR-210-3p can be used to differentiate between patients with pancreatic ductal adenocarcinoma and chronic pancreatitis. Biomed Rep 2021;14:10. [PMID: 33235725 DOI: 10.3892/br.2020.1386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
164 Smolarz B, Durczyński A, Romanowicz H, Hogendorf P. The Role of microRNA in Pancreatic Cancer. Biomedicines 2021;9:1322. [PMID: 34680441 DOI: 10.3390/biomedicines9101322] [Reference Citation Analysis]
165 Lao Y, David J, Torosian A, Placencio V, Wang Y, Hendifar A, Yang W, Tuli R. Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced pancreatic adenocarcinoma. Phys Imaging Radiat Oncol 2019;9:28-34. [PMID: 32190750 DOI: 10.1016/j.phro.2018.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Lee MJ, Na K, Shin H, Kim CY, Cho JY, Kang CM, Kim SH, Kim H, Choi HJ, Lee CK, Bae S, Son S, Paik YK. Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role. J Proteome Res 2021;20:5315-28. [PMID: 34766501 DOI: 10.1021/acs.jproteome.1c00805] [Reference Citation Analysis]
167 Park JK, Paik WH, Ryu JK, Kim YT, Kim YJ, Kim J, Song BJ, Park JM, Yoon YB. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8:e78977. [PMID: 24250822 DOI: 10.1371/journal.pone.0078977] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
168 Huang S, Chong H, Sun X, Wu Z, Jia Q, Zhang Y, Lan X. The Value of 18F-FDG PET/CT in Diagnosing Pancreatic Lesions: Comparison With CA19-9, Enhanced CT or Enhanced MR. Front Med (Lausanne) 2021;8:668697. [PMID: 34692714 DOI: 10.3389/fmed.2021.668697] [Reference Citation Analysis]
169 Sanh N, Fadul H, Hussein N, Lyn-Cook BD, Hammons G, Ramos-Cardona XE, Mohamed K, Mohammed SI. Proteomics Profiling of Pancreatic Cancer and Pancreatitis for Biomarkers Discovery. J Cell Sci Ther 2018;9:287. [PMID: 31032145 DOI: 10.4172/2157-7013.1000287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
170 Imaoka H, Sasaki M, Hashimoto Y, Watanabe K, Miyazawa S, Shibuki T, Mitsunaga S, Ikeda M. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics (Basel) 2021;11:1195. [PMID: 34209310 DOI: 10.3390/diagnostics11071195] [Reference Citation Analysis]
171 Le Calvez-Kelm F, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P, Pertesi M, Fabianova E, Adamcakova Z, Holcatova I. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget. 2016;7:78827-78840. [PMID: 27705932 DOI: 10.18632/oncotarget.12386] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 11.3] [Reference Citation Analysis]
172 Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med 2013;54:1876-82. [PMID: 24029655 DOI: 10.2967/jnumed.113.119867] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
173 Cen C, Liu L, Li X, Wu A, Liu H, Wang X, Wu H, Wang C, Han P, Wang S. Pancreatic Ductal Adenocarcinoma at CT: A Combined Nomogram Model to Preoperatively Predict Cancer Stage and Survival Outcome. Front Oncol 2021;11:594510. [PMID: 34109107 DOI: 10.3389/fonc.2021.594510] [Reference Citation Analysis]
174 Li F, Ding J. Sialylation is involved in cell fate decision during development, reprogramming and cancer progression. Protein Cell 2019;10:550-65. [PMID: 30478534 DOI: 10.1007/s13238-018-0597-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
175 Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, Thabet A, Fish MG, Teshome B, Fosbenner K, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Ryan DP, Giantonio B, Goyal L, Nipp RD, Roeland E, Weekes CD, Wo JY, Zhu AX, Dias-Santagata D, Iafrate AJ, Lennerz JK, Hong TS, Siravegna G, Horick N, Clark JW, Corcoran RB. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res 2020;26:1877-85. [PMID: 31941831 DOI: 10.1158/1078-0432.CCR-19-3467] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
176 Zhang K, Hua YQ, Wang D, Chen LY, Wu CJ, Chen Z, Liu LM, Chen H. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med 2019;17:30. [PMID: 30658662 DOI: 10.1186/s12967-019-1782-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
177 Cao J, Fu Z, Gao L, Wang X, Cheng S, Wang X, Ren H. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma. World J Surg Oncol 2017;15:48. [PMID: 28219450 DOI: 10.1186/s12957-017-1104-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
178 Brezgyte G, Shah V, Jach D, Crnogorac-Jurcevic T. Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer-A Comprehensive Review. Cancers (Basel) 2021;13:2722. [PMID: 34072842 DOI: 10.3390/cancers13112722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
179 Berger AW, Schwerdel D, Ettrich TJ, Hann A, Schmidt SA, Kleger A, Marienfeld R, Seufferlein T. Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Oncotarget 2018;9:2076-85. [PMID: 29416754 DOI: 10.18632/oncotarget.23330] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
180 Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013;10:607-620. [PMID: 23856888 DOI: 10.1038/nrgastro.2013.120] [Cited by in Crossref: 143] [Cited by in F6Publishing: 142] [Article Influence: 15.9] [Reference Citation Analysis]
181 Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018;9:29820-29841. [PMID: 30038723 DOI: 10.18632/oncotarget.25661] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]
182 Wu Y, Zhou Q, Guo F, Chen M, Tao X, Dong D. S100 Proteins in Pancreatic Cancer: Current Knowledge and Future Perspectives. Front Oncol 2021;11:711180. [PMID: 34527585 DOI: 10.3389/fonc.2021.711180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Hadano N, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N, Sueda T, Hiyama E. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer 2016;115:59-65. [PMID: 27280632 DOI: 10.1038/bjc.2016.175] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 13.7] [Reference Citation Analysis]
184 Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020;21. [PMID: 32512697 DOI: 10.3390/ijms21114012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 18.5] [Reference Citation Analysis]
185 Tewari M. Pancreatic Cancer: a Challenge to Cure. Indian J Surg 2015;77:350-7. [PMID: 26722196 DOI: 10.1007/s12262-015-1369-6] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
186 Anger F, Döring A, van Dam J, Lock JF, Klein I, Bittrich M, Germer CT, Wiegering A, Kunzmann V, van Eijck C, Löb S. Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria. Ann Surg Oncol 2021;28:2325-36. [PMID: 32920720 DOI: 10.1245/s10434-020-09100-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
187 Poty S, Mandleywala K, O'Neill E, Knight JC, Cornelissen B, Lewis JS. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics 2020;10:5802-14. [PMID: 32483420 DOI: 10.7150/thno.44772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Olafsson S, Alexandersson KF, Gizurarson JGK, Hauksdottir K, Gunnarsson O, Olafsson K, Gudmundsson J, Stacey SN, Sveinbjornsson G, Saemundsdottir J, Bjornsson ES, Olafsson S, Bjornsson S, Orvar KB, Vikingsson A, Geirsson AJ, Arinbjarnarson S, Bjornsdottir G, Thorgeirsson TE, Sigurdsson S, Halldorsson GH, Magnusson OT, Masson G, Holm H, Jonsdottir I, Sigurdardottir O, Eyjolfsson GI, Olafsson I, Sulem P, Thorsteinsdottir U, Jonsson T, Rafnar T, Gudbjartsson DF, Stefansson K. Common and Rare Sequence Variants Influencing Tumor Biomarkers in Blood. Cancer Epidemiol Biomarkers Prev 2020;29:225-35. [PMID: 31666285 DOI: 10.1158/1055-9965.EPI-18-1060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
189 Del Re M, Vivaldi C, Rofi E, Vasile E, Miccoli M, Caparello C, d'Arienzo PD, Fornaro L, Falcone A, Danesi R. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci Rep 2017;7:7931. [PMID: 28801547 DOI: 10.1038/s41598-017-08297-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
190 Zhou G, Liu X, Wang X, Jin D, Chen Y, Li G, Li C, Fu D, Xu W, Wang X. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort. Onco Targets Ther 2017;10:1199-206. [PMID: 28280354 DOI: 10.2147/OTT.S116136] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
191 Lin C, Wu WC, Zhao GC, Wang DS, Lou WH, Jin DY. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2016;95:e4527. [PMID: 27495108 DOI: 10.1097/MD.0000000000004527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
192 Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4:1171-1177. [PMID: 25891650 DOI: 10.1002/cam4.459] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
193 mohamed A, Saad Y, Saleh D, Elawady R, Eletreby R, Kharalla AS, Badr E. Can Serum ICAM 1 distinguish pancreatic cancer from chronic pancreatitis? Asian Pac J Cancer Prev. 2016;17:4671-4675. [PMID: 27892682 DOI: 10.22034/apjcp.2016.17.10.4671] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
194 Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics 2019;9:1280-7. [PMID: 30867830 DOI: 10.7150/thno.29247] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
195 Benesova L, Halkova T, Bunganic B, Belsanova B, Zavoral M, Traboulsi E, Minarik M. Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer. Pathol Oncol Res. 2018;. [PMID: 30361898 DOI: 10.1007/s12253-018-0490-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
196 Xie Z, Chen X, Li J, Guo Y, Li H, Pan X, Jiang J, Liu H, Wu B. Salivary HOTAIR and PVT1 as novel biomarkers for early pancreatic cancer. Oncotarget. 2016;7:25408-25419. [PMID: 27028998 DOI: 10.18632/oncotarget.8323] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 18.8] [Reference Citation Analysis]
197 Gold G, Goh SK, Christophi C, Muralidharan V. Dilemmas and limitations interpreting carbohydrate antigen 19-9 elevation after curative pancreatic surgery: A case report. Int J Surg Case Rep 2019;54:20-2. [PMID: 30513493 DOI: 10.1016/j.ijscr.2018.11.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Rasappan K, Shaw LKRM, Chan LWM, Chuah KL, Cheng MHW. A case of raised CA 19-9 in a patient with desmoplastic fibroblastoma of the upper limb. Int Cancer Conf J 2021;10:222-7. [PMID: 34221836 DOI: 10.1007/s13691-021-00485-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
199 Yokose T, Kabe Y, Matsuda A, Kitago M, Matsuda S, Hirai M, Nakagawa T, Masugi Y, Hishiki T, Nakamura Y, Shinoda M, Yagi H, Abe Y, Oshima G, Hori S, Nakano Y, Honda K, Kashiro A, Morizane C, Nara S, Kikuchi S, Shibahara T, Itonaga M, Ono M, Minegishi N, Koshiba S, Yamamoto M, Kuno A, Handa H, Sakamoto M, Suematsu M, Kitagawa Y. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Cancers (Basel) 2020;12:E2469. [PMID: 32878320 DOI: 10.3390/cancers12092469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
200 Godinho J, Casa-Nova M, Moreira-Pinto J, Simões P, Paralta Branco F, Leal-Costa L, Faria A, Lopes F, Teixeira JA, Passos-Coelho JL. ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer-A Retrospective Analysis. Oncologist 2020;25:e284-90. [PMID: 32043787 DOI: 10.1634/theoncologist.2019-0510] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
201 Zhang X, Shi X, Lu X, Li Y, Zhan C, Akhtar ML, Yang L, Bai Y, Zhao J, Wang Y, Yao Y, Li Y, Nie H. Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples. J Cancer 2020;11:4641-51. [PMID: 32626510 DOI: 10.7150/jca.41250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Kumar AA, Buckley BJ, Ranson M. The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets. Biomolecules 2022;12:152. [DOI: 10.3390/biom12020152] [Reference Citation Analysis]
203 Guler GD, Ning Y, Ku CJ, Phillips T, McCarthy E, Ellison CK, Bergamaschi A, Collin F, Lloyd P, Scott A, Antoine M, Wang W, Chau K, Ashworth A, Quake SR, Levy S. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun 2020;11:5270. [PMID: 33077732 DOI: 10.1038/s41467-020-18965-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
204 Gu X, Zhou R, Li C, Liu R, Zhao Z, Gao Y, Xu Y. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma. BMC Cancer 2019;19:456. [PMID: 31092213 DOI: 10.1186/s12885-019-5691-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
205 Akazawa Y, Mizuno S, Fujinami N, Suzuki T, Yoshioka Y, Ochiya T, Nakamoto Y, Nakatsura T. Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery. Sci Rep 2019;9:5925. [PMID: 30976046 DOI: 10.1038/s41598-019-42392-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
206 Earl J, Barreto E, Castillo ME, Fuentes R, Rodríguez-Garrote M, Ferreiro R, Reguera P, Muñoz G, Garcia-Seisdedos D, López JV, Sainz B Jr, Malats N, Carrato A. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers (Basel) 2021;13:1612. [PMID: 33807330 DOI: 10.3390/cancers13071612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Kowalchuk RO, Lester SC, Graham RP, Harmsen WS, Zhang L, Halfdanarson TR, Smoot RL, Gits HC, Ma WW, Owen D, Mahipal A, Miller RC, Wittich MAN, Cleary SP, McWilliams RR, Haddock MG, Hallemeier CL, Truty MJ, Merrell KW. Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Front Oncol 2021;11:651119. [PMID: 34046346 DOI: 10.3389/fonc.2021.651119] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer. 2014;111:1772-1779. [PMID: 25137018 DOI: 10.1038/bjc.2014.462] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
209 Hanada K, Okazaki A, Hirano N, Izumi Y, Teraoka Y, Ikemoto J, Kanemitsu K, Hino F, Fukuda T, Yonehara S. Diagnostic strategies for early pancreatic cancer. J Gastroenterol. 2015;50:147-154. [PMID: 25501287 DOI: 10.1007/s00535-014-1026-z] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
210 Loosen SH, Roderburg C, Kauertz KL, Koch A, Vucur M, Schneider AT, Binnebösel M, Ulmer TF, Lurje G, Schoening W, Tacke F, Trautwein C, Longerich T, Dejong CH, Neumann UP, Luedde T. CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Sci Rep 2017;7:16975. [PMID: 29208940 DOI: 10.1038/s41598-017-17175-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
211 Xu YF, Hannafon BN, Zhao YD, Postier RG, Ding WQ. Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer. Oncotarget. 2017;8:77028-77040. [PMID: 29100367 DOI: 10.18632/oncotarget.20332] [Cited by in Crossref: 66] [Cited by in F6Publishing: 73] [Article Influence: 13.2] [Reference Citation Analysis]
212 Castellanos JA, Merchant NB. Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol 2014;21:747-51. [PMID: 24092447 DOI: 10.1245/s10434-013-3289-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
213 Li H, Zhang SR, Xu HX, Wang WQ, Li S, Li TJ, Ni QX, Yu XJ, Liu L, Wu CT. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. J Cancer 2019;10:2670-8. [PMID: 31258775 DOI: 10.7150/jca.32072] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
214 Shiao MS, Chiablaem K, Charoensawan V, Ngamphaiboon N, Jinawath N. Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type. Front Genet 2018;9:309. [PMID: 30158952 DOI: 10.3389/fgene.2018.00309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
215 Martinez-Bosch N, Barranco LE, Orozco CA, Moreno M, Visa L, Iglesias M, Oldfield L, Neoptolemos JP, Greenhalf W, Earl J, Carrato A, Costello E, Navarro P. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Oncotarget 2018;9:32984-96. [PMID: 30250644 DOI: 10.18632/oncotarget.26034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
216 Kim K, Yoo D, Lee HS, Lee KJ, Park SB, Kim C, Jo JH, Jung DE, Song SY. Identification of potential biomarkers for diagnosis of pancreatic and biliary tract cancers by sequencing of serum microRNAs. BMC Med Genomics. 2019;12:62. [PMID: 31096984 DOI: 10.1186/s12920-019-0521-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
217 Lee JS, Park SS, Lee YK, Norton JA, Jeffrey SS. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol 2019;13:1623-50. [PMID: 31243883 DOI: 10.1002/1878-0261.12537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
218 Kang JS, Hong SY, Han Y, Sohn HJ, Lee M, Kang YH, Kim HS, Kim H, Kwon W, Jang JY. Limits of serum carcinoembryonic antigen and carbohydrate antigen 19-9 as the diagnosis of gallbladder cancer. Ann Surg Treat Res 2021;101:266-73. [PMID: 34796142 DOI: 10.4174/astr.2021.101.5.266] [Reference Citation Analysis]
219 Nguyen KT, Kalyan A, Beasley HS, Singhi AD, Sun W, Zeh HJ, Normolle D, Bahary N. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. J Gastrointest Oncol 2017;8:556-65. [PMID: 28736642 DOI: 10.21037/jgo.2017.01.23] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
220 Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16:430-438. [PMID: 23991810 DOI: 10.1111/hpb.12154] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 12.2] [Reference Citation Analysis]
221 Yoshizawa N, Sugimoto K, Tameda M, Inagaki Y, Ikejiri M, Inoue H, Usui M, Ito M, Takei Y. miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma. Oncol Lett. 2020;19:2677-2684. [PMID: 32218818 DOI: 10.3892/ol.2020.11357] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
222 Maehira H, Tsuji Y, Iida H, Mori H, Nitta N, Maekawa T, Kaida S, Miyake T, Tani M. Estimated tumor blood flow as a predictive imaging indicator of therapeutic response in pancreatic ductal adenocarcinoma: use of three-phase contrast-enhanced computed tomography. Int J Clin Oncol 2021. [PMID: 34783936 DOI: 10.1007/s10147-021-02066-9] [Reference Citation Analysis]
223 Czarnecka AM, Korzeń P, Nowak-Dement A, Kukwa W, Korniluk J, Szczylik C. Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer. Oncol Lett 2016;11:1101-4. [PMID: 26893699 DOI: 10.3892/ol.2015.4009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
224 Rodrigues T, Boike JR. Biliary Strictures: Etiologies and Medical Management. Semin Intervent Radiol 2021;38:255-62. [PMID: 34393335 DOI: 10.1055/s-0041-1731086] [Reference Citation Analysis]
225 Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget 2017;8:97769-86. [PMID: 29228650 DOI: 10.18632/oncotarget.22080] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
226 Słotwiński R, Słotwińska SM. Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer. Cent Eur J Immunol 2016;41:392-403. [PMID: 28450803 DOI: 10.5114/ceji.2016.65139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
227 Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 — tumor marker: Past, present, and future. World J Gastrointest Surg 2020; 12(12): 468-490 [PMID: 33437400 DOI: 10.4240/wjgs.v12.i12.468] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
228 Zhao Z, Zhao G, Yang S, Zhu S, Zhang S, Li P. The significance of exosomal RNAs in the development, diagnosis, and treatment of pancreatic cancer. Cancer Cell Int 2021;21:364. [PMID: 34243775 DOI: 10.1186/s12935-021-02059-8] [Reference Citation Analysis]
229 Wang X, Fu XH, Qian ZL, Zhao T, Duan AQ, Ruan X, Zhu B, Yin L, Zhang YJ, Yu WL. Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: A prospective cohort study. Transl Oncol 2021;14:100908. [PMID: 33059123 DOI: 10.1016/j.tranon.2020.100908] [Reference Citation Analysis]
230 Shin K, Jung EK, Park SJ, Jeong S, Kim IH, Lee MA. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. World J Gastrointest Oncol 2021; 13(8): 915-928 [PMID: 34457195 DOI: 10.4251/wjgo.v13.i8.915] [Reference Citation Analysis]
231 Goh TS, Ha M, Lee JS, Jeong DC, Jung ES, Han ME, Kim YH, Oh SO. Prognostic significance of EIF4G1 in patients with pancreatic ductal adenocarcinoma. Onco Targets Ther 2019;12:2853-9. [PMID: 31043796 DOI: 10.2147/OTT.S202101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
232 Jeon SK, Lee JM, Lee ES, Yu MH, Joo I, Yoon JH, Jang JY, Lee KB, Lee SH. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers. Eur Radiol 2021. [PMID: 34170366 DOI: 10.1007/s00330-021-08108-0] [Reference Citation Analysis]
233 Rajan R, Baqar A, Menon T. An interesting case of primary squamous cell carcinoma of the colon with synchronous metastatic adenocarcinoma. Clin Case Rep 2014;2:323-5. [PMID: 25548638 DOI: 10.1002/ccr3.127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
234 Meijer LL, Puik JR, Le Large TYS, Heger M, Dijk F, Funel N, Wurdinger T, Garajová I, van Grieken NCT, van de Wiel MA, Giovannetti E, Kazemier G. Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. Cancers (Basel) 2019;11:E1181. [PMID: 31443224 DOI: 10.3390/cancers11081181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
235 Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, Ishikawa H, Kakizawa N, Saito M, Futsuhara K, Noda H, Konishi F, Rikiyama T. Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients. Sci Rep 2021;11:20797. [PMID: 34675229 DOI: 10.1038/s41598-021-00060-9] [Reference Citation Analysis]
236 Zaheer A, Haider M, Kawamoto S, Hruban RH, Fishman EK. Dual-phase CT findings of groove pancreatitis. Eur J Radiol 2014;83:1337-43. [PMID: 24935140 DOI: 10.1016/j.ejrad.2014.05.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
237 Ren H, Wu CR, Aimaiti S, Wang CF. Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma. Oncol Lett 2020;19:4093-105. [PMID: 32382348 DOI: 10.3892/ol.2020.11495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]